The Food and Drug Administration on Sunday issued an emergency use authorization for hydroxychloroquine and chloroquine, decades-old malaria drugs championed by President Donald Trump for coronavirus treatment based on a promising trial out of France.
The agency allowed for the drugs to be “donated to the Strategic National Stockpile to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible,” HHS said in a statement, announcing that Sandoz donated 30 million doses of hydroxychloroquine to the stockpile and Bayer donated 1 million doses of chloroquine.
Dr. Aileen Marty is an infectious diseases expert at FIU and she told the South Florida Morning Show that the emergency approval of cholorquine will make a big difference therapeutically in stopping the spread and in treating those who are already sick.
The move was supported by the White House, part of a larger Trump-backed effort to speed the use of anti-malaria drugs as a potential therapy for a virus that has no proven treatment or cure. FDA already has allowed New York state to test administering the medication to seriously ill patients, and some hospitals have added it to their treatment protocols.
“Let’s see how it works,” Trump said at a press briefing on Sunday, referencing New York state’s efforts. “It may. It may not.”
“Scientists in America and around the world have identified multiple potential therapeutics for COVID19, including chloroquine and hydroxychloroquine,” HHS Secretary Alex Azar tweeted on Sunday night, praising Trump and the EUA.
Listen to entire interview with expert Dr. Aileen Marty here.